ASHEVILLE, N.C., July 29 /PRNewswire/ -- DoctorDirectory.com, Inc. announced that it is partnering with DAVA Pharmaceuticals, Inc. to co-market VoSpire ER(R) (Albuterol Sulfate) Extended-Release Tablets through its IncreaseRx(R) virtual marketing solution. IncreaseRx utilizes web-based educational and promotional tactics to reach tens of thousands of interested prescribers with targeted sales and marketing messages. Essentially, IncreaseRx performs as a virtual contract sales organization providing e-sampling and online educational tools. "Our team is looking forward to promoting VoSpire ER(R) with DAVA. Albuterol sulfate remains a standard of long-lasting oral therapy for patients," said Jay Grobowsky, CEO for DoctorDirectory.
VoSpire ER(R) is indicated for the relief of bronchospasm in adults and children 6 years of age and older with reversible obstructive airway disease.
"We at DAVA felt that the DoctorDirectory team and the IncreaseRx solution were an excellent fit for the continued promotion of VoSpire ER(R). The strength of IncreaseRx is in its ability to reach far more prescribers than we could have by utilizing a traditional sales force model. The value-based relationship that DoctorDirectory has with its physicians gives our brand a particularly attractive solution," said Liad Spiro, Senior Director, Commercialization and Marketing for DAVA.
DoctorDirectory is a marketing solutions company that specializes in providing brand teams and their agencies web-based access to Healthcare Professionals. IncreaseRx is a whitespace strategy designed to reach under-performing or inaccessible physician segments and generate incremental revenue from unrealized potential. It utilizes a suite of traditional and web-based tactics to generate incremental revenue for any pharma brand regardless of product life cycle.
For more information about DoctorDirectory or IncreaseRx, contact Jay Grobowsky at 828-255-0252 or by email at firstname.lastname@example.org.
DAVA Pharmaceuticals, Inc. is a global pharmaceutical company committed to providing cost-effective pharmaceutical products to the healthcare market by integrating expertise in product development, manufacturing and marketing with global strategic alliances to deliver medicines from the source.
For more information about DAVA Pharmaceuticals, Inc., contact Liad Spiro at 201-947-7442 or by email at LSpiro@davapharma.com.
This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.
|SOURCE DoctorDirectory.com, Inc.|
Copyright©2008 PR Newswire.
All rights reserved